Latest news
25 items- PRPsychemedics Releases 2025 Workforce Insights ReportDALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats empl
- PRPsychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing InsightsDALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate's or employee's test results fall within a range of positive reports collected over the past 12 months. By segmenting results into four quartiles – Lower, Median, Upper, and Highest – this advanced reporting provides real-time context and bench
- SECSEC Form 15-12G filed by Psychemedics Corporation15-12G - PSYCHEMEDICS CORP (0000806517) (Filer)
- INSIDERLarge owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)4 - PSYCHEMEDICS CORP (0000806517) (Issuer)
- SECSEC Form 25 filed by Psychemedics Corporation25 - PSYCHEMEDICS CORP (0000806517) (Filer)
- INSIDERLarge owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)4 - PSYCHEMEDICS CORP (0000806517) (Issuer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Psychemedics CorporationSC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)
- INSIDERDirector Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)4 - PSYCHEMEDICS CORP (0000806517) (Issuer)
- SECAmendment: SEC Form SC 13E3/A filed by Psychemedics CorporationSC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)
- SECPsychemedics Corporation filed SEC Form 8-K: Other Events8-K - PSYCHEMEDICS CORP (0000806517) (Filer)
- INSIDERNew insider Powell Anderson Capital Partners Llc claimed ownership of 737,565 shares (SEC Form 3)3 - PSYCHEMEDICS CORP (0000806517) (Issuer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Psychemedics CorporationSC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)
- INSIDERDirector Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)4 - PSYCHEMEDICS CORP (0000806517) (Issuer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Psychemedics CorporationSC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)
- SECPsychemedics Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - PSYCHEMEDICS CORP (0000806517) (Filer)
- PRPsychemedics Corporation Announces Reverse and Forward Stock SplitDALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) (the "Company"), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the "Reverse Stock Split") followed immediately by a 5,000-for-1 forward stock split of its common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Stock Split"), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 202
- SECPsychemedics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PSYCHEMEDICS CORP (0000806517) (Filer)
- SECSEC Form DEFA14A filed by Psychemedics CorporationDEFA14A - PSYCHEMEDICS CORP (0000806517) (Filer)
- PRPsychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of StockholdersDALLAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing, reminds its stockholders to vote ahead of the Company's upcoming annual meeting of stockholders scheduled for November 25, 2024. Each stockholder's vote is important. The Company's Board of Directors recommends that stockholders vote "FOR" each proposal at the annual meeting. Instructions for voting your shares are set forth below. The record date for the annual meeting is October 8, 2024. If you have previously voted your shares and do not wish to change your vote, you do not need to take any action. If you have already voted or given your proxy and wish to change your vote,
- SECSEC Form 10-Q filed by Psychemedics Corporation10-Q - PSYCHEMEDICS CORP (0000806517) (Filer)
- SECPsychemedics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PSYCHEMEDICS CORP (0000806517) (Filer)
- PRPsychemedics Corporation Reports Third Quarter 2024 Financial ResultsDALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ending September 30, 2024. The Company's revenue for three months ended September 30, 2024, was $5.2 million versus $5.7 million for three months ended September 30, 2023, a decrease of 9%. Net loss was $0.5 million, or $0.09 per share, compared to a net loss of $2.1 million, or $0.36 per share, for the three months ended September 2024 and 2023, respectively. The Company's revenue for nine months ended September 30, 2024, was $15.3 million versus $17.1 million for nine months ended Septem
- SECAmendment: SEC Form SC 13E3/A filed by Psychemedics CorporationSC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)
- SECSEC Form DEF 14A filed by Psychemedics CorporationDEF 14A - PSYCHEMEDICS CORP (0000806517) (Filer)
- SECAmendment: SEC Form SC 13E3/A filed by Psychemedics CorporationSC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)